Lv4
446 积分 2023-06-15 加入
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
3小时前
已完结
Membranous nephropathy: new pathogenic mechanisms and their clinical implications
10天前
已完结
Advancements and challenges in CAR T cell therapy in autoimmune diseases
4个月前
已完结
The tyranny of non-inferiority trials
4个月前
已完结
Advancements and challenges in CAR T cell therapy in autoimmune diseases
5个月前
已完结
Chimeric antigen receptor T cell therapy for autoimmune disease
5个月前
已完结
Forks in the road for CAR T and CAR NK cell cancer therapies
5个月前
已完结
Belantamab mafodotin in patients with relapsed/refractory AL amyloidosis with myeloma
6个月前
已完结
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
6个月前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
6个月前
已完结
皖公网安备34019202002308
